Dianthus Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 5, 2020 and accepted by EDGAR at Nov 5, 2020, 08:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $0 | us-gaap:Revenues |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $0 | us-gaap:Revenues |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $11.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $38.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$18.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$59.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$17.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$56.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.37 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$1.34 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$50.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $187.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $141.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $164.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $174.6m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $9.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $16.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $158.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-20-286283. Last ingested by Listed: Nov 13, 2026, 16:49 ET. Listed shows no prices and gives no investment advice.